IL ‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.19898 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von A Reimer-Taschenbrecker und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical Faculty and Medical Center, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Interleukin-6, Cytokines, Epidermolysis Bullosa. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Berta-Ottenstein Programm, Deutsche Forschungsgemeinschaft, DEBRA International.
Abstract (Originalsprache)
Background
Systemic inflammation is considered a major player in the pathogenesis of epidermolysis bullosa (EB), but its pattern has only been described in small heterogeneous cohorts. There is controversy if and how systemic inflammation should be therapeutically targeted.
Methods
We examined serum proinflammatory, anti‐inflammatory, and itch related cytokines in a paediatric cohort of 29 patients with junctional and dystrophic EB. The cytokine that emerged as the most relevant was measured in a validation cohort of 42 patients during follow‐up visits over 2 years.
Results
IL‐6 showed the most consistent and highest aberration dominating systemic inflammation. IL‐6 correlated with wound body surface area (BSA) in both, finding and validation cohorts. Patients with less than 3% wound BSA had normal IL‐6, while IL‐6 levels significantly increased at more than 5% and 10% of wound BSA. TGF‐β was only marginally elevated in patients with severe recessive dystrophic EB, while TNF‐α, IFN‐γ and IL‐1β varied inconsistently. Patients reporting itch showed elevations in type 2 immunity (IgE, TSLP, IL4 and/or IL‐31, respectively).
Conclusions
Our data suggest a dominant skin barrier and wound healing inflammatory pattern in junctional and dystrophic EB that depends on the wound area and not on the EB type. In EB, itch mediators may be similar to other pruritic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Medical Faculty and Medical Center, University of Freiburg, Freiburg, Germany.
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Institute of Medical Biometry and Statistics, Medical Faculty and Medical Center, University of Freiburg, Freiburg, Germany.
ORCID-Profile: A Reimer-Taschenbrecker, K Eyerich, C Has
Förderung
- Berta-Ottenstein Programm
- Deutsche Forschungsgemeinschaft
- DEBRA International
Zitieren
APA
Reimer-Taschenbrecker, A., Hess, M., Davidovic, M., Hwang, A., Hübner, S., Hofsaess, M., Gewert, S., Eyerich, K., & Has, C. (2025). IL ‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19898
Vancouver
Reimer-Taschenbrecker A, Hess M, Davidovic M, Hwang A, Hübner S, Hofsaess M, et al. IL ‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.19898
BibTeX
@article{ReimerTaschenbrecker2025,
author = {Reimer-Taschenbrecker, A and Hess, M and Davidovic, M and Hwang, A and Hübner, S and Hofsaess, M and Gewert, S and Eyerich, K and Has, C},
title = {IL ‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.19898}
}
EUVIMED